ADMA ADMA Biologics
ADMA Biologics (ADMA) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is $0.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.4% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About ADMA Biologics
ADMA Biologics Inc along with its wholly owned subsidiary is a late stage biopharmaceutical company that develops, manufactures, and markets specialty plasma-based biologics for the treatment and prevention of certain infectious diseases.
Sector
Healthcare
Industry
Drug Manufacturers/Other